With hepatitis C in freefall, Gilead's bottoming out. The good news? It's bottoming out

2nd May 2018 Uncategorised 0

Gilead Sciences may have some exciting prospects on the horizon, but for now, its cash-cow hepatitis C business is a big drag. After hepatitis C sales cratered in the first quarter—falling even more than expected—its CFO admitted that the company’s bottoming out. The good news? A trough implies growth ahead.

More: With hepatitis C in freefall, Gilead's bottoming out. The good news? It's bottoming out
Source: fierce